LinkedIn Profile

Access Endocyte historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:ecyt 1120203 Oct 18th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 17th, 2019 10:21PM Oct 17th, 2019 10:21PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 17th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 17th, 2019 08:37AM Oct 17th, 2019 08:37AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 16th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 15th, 2019 10:22PM Oct 15th, 2019 10:22PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 15th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 15th, 2019 10:26AM Oct 15th, 2019 10:26AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 14th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 14th, 2019 11:01AM Oct 14th, 2019 11:01AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 13th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 13th, 2019 07:43AM Oct 13th, 2019 07:43AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 12th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 12th, 2019 09:33AM Oct 12th, 2019 09:33AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 11th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 11th, 2019 01:14PM Oct 11th, 2019 01:14PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 10th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 9th, 2019 10:20PM Oct 9th, 2019 10:20PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Oct 9th, 2019 12:00AM Endocyte 2.5K 66.00 Open Pharmaceuticals Oct 9th, 2019 12:48PM Oct 9th, 2019 12:48PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, Companion Imaging Open Purdue Research Park, 3000 Kent Avenue West Lafayette IN US 47906 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.